Seres Therapeutics (MCRB) Equity Average: 2015-2025
Historic Equity Average for Seres Therapeutics (MCRB) over the last 10 years, with Sep 2025 value amounting to $38.3 million.
- Seres Therapeutics' Equity Average rose 221.36% to $38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.3 million, marking a year-over-year increase of 221.36%. This contributed to the annual value of -$15.5 million for FY2024, which is 8.81% up from last year.
- Latest data reveals that Seres Therapeutics reported Equity Average of $38.3 million as of Q3 2025, which was down 8.11% from $41.7 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Equity Average ranged from a high of $159.2 million in Q1 2021 and a low of -$73.4 million during Q2 2024.
- Moreover, its 3-year median value for Equity Average was -$12.6 million (2023), whereas its average is -$7.6 million.
- In the last 5 years, Seres Therapeutics' Equity Average soared by 389.58% in 2021 and then crashed by 943.08% in 2024.
- Seres Therapeutics' Equity Average (Quarterly) stood at $153.6 million in 2021, then tumbled by 74.49% to $39.2 million in 2022, then slumped by 176.54% to -$30.0 million in 2023, then skyrocketed by 162.86% to $18.9 million in 2024, then soared by 221.36% to $38.3 million in 2025.
- Its last three reported values are $38.3 million in Q3 2025, $41.7 million for Q2 2025, and $32.1 million during Q1 2025.